Plus Therapeutics (NASDAQ:PSTV) Downgraded to “Hold” Rating by Zacks Research

Plus Therapeutics (NASDAQ:PSTV) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Maxim Group decreased their price target on Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, August 18th. D Boral Capital raised Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. HC Wainwright dropped their price target on Plus Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Monday, November 3rd. Wall Street Zen raised shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, D. Boral Capital reissued a “buy” rating and issued a $5.00 target price on shares of Plus Therapeutics in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Plus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

Plus Therapeutics Stock Performance

Shares of NASDAQ:PSTV opened at $0.56 on Tuesday. The stock’s 50-day simple moving average is $0.57 and its two-hundred day simple moving average is $0.49. The stock has a market capitalization of $76.55 million, a price-to-earnings ratio of -0.25 and a beta of 0.77. Plus Therapeutics has a 52-week low of $0.16 and a 52-week high of $2.31.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The business had revenue of $1.40 million for the quarter, compared to analyst estimates of $1.50 million. As a group, equities analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Insider Transactions at Plus Therapeutics

In other news, Director Robert P. Lenk acquired 110,000 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were acquired at an average cost of $0.49 per share, with a total value of $53,900.00. Following the acquisition, the director directly owned 139,327 shares of the company’s stock, valued at approximately $68,270.23. The trade was a 375.08% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.79% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PSTV. Altium Capital Management LLC purchased a new stake in Plus Therapeutics during the third quarter valued at $628,000. Jane Street Group LLC bought a new position in shares of Plus Therapeutics in the 2nd quarter valued at about $41,000. Finally, Virtu Financial LLC purchased a new position in Plus Therapeutics in the first quarter worth about $38,000. 3.28% of the stock is owned by hedge funds and other institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.